Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CAR-NK Cell Therapy
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : OmniaBio
Deal Size : Undisclosed
Deal Type : Partnership
Details : The partnership will enable the development and manufacturing of Catamaran Bio’s allogeneic chimeric antigen receptor (CAR)-NK cell therapies for the treatment of solid tumors.
Brand Name : Undislcosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 14, 2023
Lead Product(s) : CAR-NK Cell Therapy
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : OmniaBio
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : CAR-NK Cell Therapy
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : MaxCyte
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : CAT-248 is a CAR-NK cell therapy targeting CD70 positive tumors. CAT-248 has been engineered with four functional modifications: an optimized CAR that targets CD70, an IL-15 cytokine, a TME-switch, and the elimination of CD70 expression to enable scalabl...
Brand Name : CAT-248
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 03, 2023
Lead Product(s) : CAR-NK Cell Therapy
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : MaxCyte
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : CAT-248
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CAT-248 is company's off-the-shelf CAR-NK cell therapy targeting CD70 positive tumors. CAT-248 has been modified as an optimized CAR that targets CD70 and an IL-15 cytokine that promotes persistence and enhanced NK cell activity.
Brand Name : CAT-248
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 05, 2022
Lead Product(s) : CAT-248
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : CAR-NK Cell Therapy
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CAR-NK cells engineered with this TGFβ DNR demonstrated reduction of downstream TGFβactivity as shown by >90% reduction of SMAD2 phosphorylation (a downstream signal of TGFβ activity) even at supraphysiological doses of TGFβ.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 16, 2022
Lead Product(s) : CAR-NK Cell Therapy
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : CAT-179
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CAT-179 has been engineered with three functional modifications: an optimized CAR that targets HER2, an IL-15 cytokine that promotes persistence and enhanced NK cell activity, and a TME-switch that neutralizes effects of TGFβ immunosuppressive found in ...
Brand Name : CAT-179
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 02, 2022
Lead Product(s) : CAT-179
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : CAT-179
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CAT-179 was efficiently engineered (45% CAR+) from donor-derived NK cells using non-viral TcBuster transposon system, incorporating a multi-cistronic cargo containing HER2 CAR, IL15, and TGFβ dominant-negative receptor (TGFβ DNR).
Brand Name : CAT-179
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 08, 2022
Lead Product(s) : CAT-179
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : This expanded collaboration and license shows the commitment to develop and integrate the most advanced technologies for manufacturing of allogeneic CAR-NK cell therapies, and will optimize the TcBuster transposon system which has been integrated into TA...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 14, 2022
Lead Product(s) : CAT-179
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CAT-179, been engineered with three functional modification: an optimized CAR that target HER2, an IL-15 cytokine that promotes persistence and enhanced NK cell activity, and a TME-switch that neutralizes effects of TGFβ immunosuppressive signal found i...
Brand Name : CAT-179
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
March 09, 2022
Lead Product(s) : CAT-179
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : CAT-248
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The data support advancement of CAT-248, Catamaran’s lead CAR-NK cell therapy candidate, which is directed against CD70, a tumor antigen that is highly expressed on certain types of cancers including renal cell carcinoma, glioma, pancreatic cancer, and...
Brand Name : CAT-248
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
December 13, 2021
Lead Product(s) : CAT-248
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : CAR-NK cell therapies
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Sofinnova Partners
Deal Size : $42.0 million
Deal Type : Series A Financing
Details : Proceeds will be used to advance the company’s two lead chimeric antigen receptor (CAR)-NK cell therapy programs and will expand the company’s TAILWIND™ Platform.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 23, 2020
Lead Product(s) : CAR-NK cell therapies
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Sofinnova Partners
Deal Size : $42.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?